Willie Wilson

1.7k total citations · 1 hit paper
20 papers, 1.4k citations indexed

About

Willie Wilson is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Willie Wilson has authored 20 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Immunology and 5 papers in Oncology. Recurrent topics in Willie Wilson's work include Immunotherapy and Immune Responses (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Phagocytosis and Immune Regulation (4 papers). Willie Wilson is often cited by papers focused on Immunotherapy and Immune Responses (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Phagocytosis and Immune Regulation (4 papers). Willie Wilson collaborates with scholars based in United States, Türkiye and Germany. Willie Wilson's co-authors include Albert S. Baldwin, Phillip A. Dennis, Shigeru Kawabata, Joell J. Gills, Kristin J. Lastwika, Janis M. Taube, Sheng Yao, Hiroshi Kitagawa, Linda N. Liu and Jeffrey W. Norris and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Molecular and Cellular Biology.

In The Last Decade

Willie Wilson

18 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

2015 643 citations Kristin J. Lastwika, Willie Wilson et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Willie Wilson United States	10	667	657	410	257	226	20	1.4k
Teruaki Fujishita Japan	16	583 0.9×	408 0.6×	234 0.6×	222 0.9×	107 0.5×	23	1.1k
Emanuel Petricoin United States	10	669 1.0×	817 1.2×	361 0.9×	301 1.2×	74 0.3×	12	1.3k
Xiaoying Shi China	12	890 1.3×	641 1.0×	327 0.8×	284 1.1×	369 1.6×	31	1.6k
Franziska van Zijl Austria	11	824 1.2×	604 0.9×	193 0.5×	371 1.4×	164 0.7×	13	1.6k
Clara Campàs Spain	16	773 1.2×	385 0.6×	161 0.4×	211 0.8×	131 0.6×	20	1.2k
Susan E. Bray United Kingdom	20	1.1k 1.7×	711 1.1×	142 0.3×	405 1.6×	162 0.7×	40	1.7k
Sailan Zou China	9	561 0.8×	348 0.5×	226 0.6×	259 1.0×	105 0.5×	11	1.0k
Ju‐Ming Wang Taiwan	16	801 1.2×	505 0.8×	410 1.0×	217 0.8×	83 0.4×	27	1.4k
Krasil'nikov Ma Russia	16	851 1.3×	419 0.6×	160 0.4×	288 1.1×	75 0.3×	60	1.2k
Quan Lin China	16	378 0.6×	441 0.7×	190 0.5×	133 0.5×	248 1.1×	49	938

Countries citing papers authored by Willie Wilson

Since Specialization

Citations

This map shows the geographic impact of Willie Wilson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Willie Wilson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Willie Wilson more than expected).

Fields of papers citing papers by Willie Wilson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Willie Wilson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Willie Wilson. The network helps show where Willie Wilson may publish in the future.

Co-authorship network of co-authors of Willie Wilson

This figure shows the co-authorship network connecting the top 25 collaborators of Willie Wilson. A scholar is included among the top collaborators of Willie Wilson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Willie Wilson. Willie Wilson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Le, Robert Q., Kamar Godder, Moran Choe, et al.. (2025). FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy. Clinical Cancer Research. 31(17). 3607–3612.

Wilson, Willie, Isra Darwech, Gabriela Andrejeva, et al.. (2020). Pre-Clinical Combination of AO-176, a Highly Differentiated Clinical Stage CD47 Antibody, with Either Azacitidine or Venetoclax Significantly Enhances DAMP Induction and Phagocytosis of Acute Myeloid Leukemia. Blood. 136(Supplement 1). 9–10. 2 indexed citations

Wilson, Willie. (2019). The regulation of constitutive NF-κB activity by glycogen synthase kinase-3 in pancreatic cancer. Carolina Digital Repository (University of North Carolina at Chapel Hill).

Richards, John O., Myriam N. Bouchlaka, Robyn J. Puro, et al.. (2019). Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination. Blood. 134(Supplement_1). 1844–1844. 5 indexed citations

Capoccia, Benjamin J., Ronald R. Hiebsch, Robyn J. Puro, et al.. (2019). Abstract A147: AO-176, a next-generation anti-CD47 antibody, induces immunogenic cell death. Cancer Immunology Research. 7(2_Supplement). A147–A147. 1 indexed citations

Wilson, Willie, Myriam N. Bouchlaka, Ben Capoccia, et al.. (2018). Therapeutic Potential of AO-176, a Next Generation Humanized CD47 Antibody, for Hematologic Malignancies. Blood. 132(Supplement 1). 4180–4180. 4 indexed citations

Zdanov, Stéphanie, Magis Mandapathil, Rasha Abu Eid, et al.. (2016). Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells. Cancer Immunology Research. 4(4). 354–365. 127 indexed citations

Lastwika, Kristin J., Willie Wilson, Qing Kay Li, et al.. (2015). Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer. Cancer Research. 76(2). 227–238. 643 indexed citations breakdown →

Doğan, İrem, Shigeru Kawabata, Emily Anne Smith Bergbower, et al.. (2014). SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines. Lung Cancer. 85(1). 1–6. 25 indexed citations

10.

Kawabata, Shigeru, M. Christine Hollander, Danielle Donahue, et al.. (2014). Rapamycin Prevents the Development and Progression of Mutant Epidermal Growth Factor Receptor Lung Tumors with the Acquired Resistance Mutation T790M. Cell Reports. 7(6). 1824–1832. 23 indexed citations

11.

Wilson, Willie, et al.. (2013). GSK-3α Promotes Oncogenic KRAS Function in Pancreatic Cancer via TAK1–TAB Stabilization and Regulation of Noncanonical NF-κB. Cancer Discovery. 3(6). 690–703. 73 indexed citations

12.

Lastwika, Kristin J., Willie Wilson, & Phillip A. Dennis. (2013). Abstract 4981: PI3K/AKT/mTOR pathway activation drives expression of the immune inhibitory ligand PD-L1 in NSCLC.. Cancer Research. 73(8_Supplement). 4981–4981. 6 indexed citations

13.

Wilson, Willie & Glenn Merlino. (2013). Flipping the phenotypic switch on a novel antimelanoma differentiation strategy. Pigment Cell & Melanoma Research. 26(6). 791–793. 1 indexed citations

14.

Wilson, Willie & Albert S. Baldwin. (2008). Maintenance of Constitutive IκB Kinase Activity by Glycogen Synthase Kinase-3α/β in Pancreatic Cancer. Cancer Research. 68(19). 8156–8163. 99 indexed citations

15.

Steinbrecher, Kris A., Willie Wilson, Patricia C. Cogswell, & Albert S. Baldwin. (2005). Glycogen Synthase Kinase 3β Functions To Specify Gene-Specific, NF-κB-Dependent Transcription. Molecular and Cellular Biology. 25(19). 8444–8455. 180 indexed citations

16.

Chi, Xuan, et al.. (2005). Complex cardiac Nkx2-5 gene expression activated by noggin-sensitive enhancers followed by chamber-specific modules. Proceedings of the National Academy of Sciences. 102(38). 13490–13495. 32 indexed citations

17.

Wilson, Willie, Fernando Pardo‐Manuel de Villena, Beverly Lyn‐Cook, et al.. (2004). Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics. 84(4). 707–714. 114 indexed citations

18.

Chatterjee, Pradeep K., et al.. (2004). Selecting transpositions using phage P1 headful packaging: new markerless transposons for functionally mapping long-range regulatory sequences in bacterial artificial chromosomes and P1-derived artificial chromosomes. Analytical Biochemistry. 335(2). 305–315. 9 indexed citations

19.

Braun, Rod D., et al.. (2002). Hemodynamic parameters in blood vessels in choroidal melanoma xenografts and rat choroid.. PubMed. 43(9). 3045–52. 18 indexed citations

20.

Glass, PSA, et al.. (1989). Is the Priming Principle Both Effective and Safe?. Survey of Anesthesiology. 4(2). 207–207. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact